We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+12.64%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.53B
AUM Growth
+$116M
Cap. Flow
-$73.8M
Cap. Flow %
-2.09%
Top 10 Hldgs %
47.92%
Holding
99
New
17
Increased
28
Reduced
21
Closed
18

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$51.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$50.1M
3
FOLD
Amicus Therapeutics
FOLD
+$40.3M
4
CNC icon
Centene
CNC
+$37.3M
5
STOK icon
Stoke Therapeutics
STOK
+$27.4M

Top Sells

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$82.5M
2
ARRY
Array Biopharma Inc
ARRY
+$62.3M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$49.3M
4
PEN icon
Penumbra
PEN
+$47.5M
5
XNCR icon
Xencor
XNCR
+$46.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.51%
2 Miscellaneous 2.32%
3 Financials 2.17%
4 Energy 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNC icon
26
Centene
CNC
$32B
$36.2M 1.03%
+690,870
New +$37.3M
GRTS
27
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$35.8M 1.01%
3,215,994
+862,259
+37% +$9.86M
UNH icon
28
UnitedHealth
UNH
$353B
$34.6M 0.98%
141,901
+9,011
+7% +$2.17M
ANAB icon
29
AnaptysBio
ANAB
$1.67B
$34.4M 0.97%
609,658
+112,740
+23% +$8.12M
XERS icon
30
Xeris Biopharma Holdings
XERS
$1.55B
$34.3M 0.97%
3,000,641
– –
SYRS
31
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$33.5M 0.95%
362,038
+197,518
+120% +$13.8M
AXNX
32
DELISTED
Axonics, Inc. Common Stock
AXNX
$33.3M 0.94%
813,500
+214,900
+36% +$6.04M
REPL icon
33
Replimune Group
REPL
$1.46B
$32.2M 0.91%
2,197,003
-15,453
-0.7% -$223K
TDOC icon
34
Teladoc Health
TDOC
$1.18B
$30.7M 0.87%
461,880
+21,980
+5% +$1.28M
LIVN icon
35
LivaNova
LIVN
$4.43B
$30.5M 0.86%
423,987
-158,700
-27% -$11.6M
IMGN
36
DELISTED
Immunogen Inc
IMGN
$30.3M 0.86%
13,954,794
+891,027
+7% +$2.11M
STOK icon
37
Stoke Therapeutics
STOK
$2.04B
$29.8M 0.84%
+1,021,808
New +$27.4M
EIDX
38
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$27.3M 0.77%
878,403
+26,503
+3% +$718K
ODT
39
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$27.2M 0.77%
740,671
+263,207
+55% +$6.31M
DXCM icon
40
DexCom
DXCM
$34.3B
$25.8M 0.73%
+688,400
New +$21.6M
TCRR
41
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$25.7M 0.73%
1,799,216
-8,040
-0.4% -$128K
OXFD
42
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$24.7M 0.7%
1,796,477
-204,990
-10% -$3.14M
JAZZ icon
43
Jazz Pharmaceuticals
JAZZ
$15.9B
$24M 0.68%
168,387
-101,093
-38% -$13.6M
CBIO
44
Crescent Biopharma
CBIO
$659M
$23.9M 0.68%
20,084
-98
-0.5% -$117K
CBAY
45
DELISTED
Cymabay Therapeutics
CBAY
$22.5M 0.64%
3,138,365
+194,600
+7% +$2.2M
AKRO
46
DELISTED
Akero Therapeutics
AKRO
$22.4M 0.63%
+1,168,802
New +$22.2M
VAPO
47
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$22.1M 0.62%
119,942
-6,473
-5% -$958K
BCEL
48
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$21.5M 0.61%
+1,140,306
New +$20.6M
ADPT icon
49
Adaptive Biotechnologies
ADPT
$4.02B
$20.5M 0.58%
+425,000
New +$18.8M
MOR
50
DELISTED
MorphoSys AG American Depositary Shares
MOR
$17.7M 0.5%
733,699
-160,101
-18% -$3.97M
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2019 Portfolio in Review

As of Q2 2019, Redmile Group held 99 positions worth $3.53B, up 3.4% from $3.42B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group's Q2 2019 filing shows 17 new, 28 increased, 21 reduced and 18 closed positions. Its largest new stake was Sarepta Therapeutics: 412,000 shares worth $62.6M. The largest sale was InflaRx, an estimated $82.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q2 2019 buy was Sarepta Therapeutics: 412,000 shares worth $62.6M.
  • Redmile Group added most to Tricida, Inc. Common Stock in Q2 2019, an estimated $51.2M increase.
  • Redmile Group's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $62.3M.
  • Redmile Group fully exited InflaRx in Q2 2019, selling an estimated $82.5M.
  • Redmile Group's ten largest holdings make up 48% of its $3.53B portfolio in Q2 2019.
  • Redmile Group opened 17 new positions and closed 18 in Q2 2019.
  • Redmile Group's portfolio value rose 3.4% quarter-over-quarter to $3.53B.

Based on Redmile Group's 13F filing for Q2 2019, filed 14 Aug 2019.